Agepha Pharma and Caristo Diagnostics Team Up to Fight Coronary Inflammation

Caristo Diagnostics United Kingdom England New Jersey

recently presented at the American Heart Association's Late Breaking Science Sessions has found that the CaRi-Heart® technology can predict fatal and non-fatal cardiac events independently from routine clinical risk scores and standard coronary computed tomography angiography (CCTA) interpretation, and can significantly impact treatment for CAD by transforming risk stratification and management of patients undergoing routine CCTA. Among patients who had no plaque and zero calcium at time of CCTA, those with the most abnormal CaRi-Heart test results experienced 11-fold higher risk for cardiac mortality and 5-fold higher risk for major adverse cardiac events (MACE) than those who had normal CaRi-Heart test results. The CaRi-Heart® technology is in clinical use in the UK, EU and Australia, and is limited to research use in the U.S. before the FDA grants marketing authorization.

About AGEPHA Pharma

AGEPHA Pharma is a family-owned, leading multinational pharmaceutical company focused on bringing treatments to patients who need them most. Since 1947, they have invested in proven therapies, including a wide range of pharmaceuticals, medical devices, and nutritional supplements, supported by a highly qualified team of clinical scientists and regulatory experts.

For more information, please visit AGEPHA Pharma's U.S. corporate website or follow AGEPHA Pharma on Twitter (@AGEPHAPharmaUS) and LinkedIn.

AGEPHA Pharma contact:

Laura O'Neill for AGEPHA Pharma
FINN Partners
[e-mail] 
402-499-8203

About Caristo Diagnostics Limited

Caristo Diagnostics Limited is a global leader in cardiac and vascular disease diagnostics and risk prediction. Founded in 2018 as a spin-out company from the University of Oxford, the world's #1 research university, Caristo has developed a portfolio of imaging-based and AI-assisted platforms that can be applied to aid the prediction and diagnosis of heart attack, stroke, and diabetes. Caristo was highlighted by Nature in 2020 as one of the most exciting science-based companies to have emerged from academic labs. Find Caristo online on its website, LinkedIn and X.

Caristo Diagnostics contact:

Frank Cheng, Caristo Diagnostics CEO
[e-mail]
415-230-2350

Logo - https://mma.prnewswire.com/media/2054669/4314536/Caristo_Logo.jpg
Logo - https://mma.prnewswire.com/media/2317974/AGEPHA_PHARMA_Logo.jpg

 

 

 

View original content:https://www.prnewswire.co.uk/news-releases/agepha-pharma-and-caristo-diagnostics-team-up-to-fight-coronary-inflammation-302034778.html